By 2012, 11 of the top 16 drugs in the United States will be injectable or infusible, and by 2014, specialty pharmaceuticals will comprise the bulk of drug spending in the United States.
BY 2012, ELEVEN OF THE top 16 drugs in the United States will be injectable or infusible, and by 2014, specialty pharmaceuticals will comprise the bulk of drug spending in the United States, according to a new report from ICORE Healthcare, a subsidiary of Magellan Health Services.
"The world of pharmacy management and drug management is at an inflection point that is being driven by the change in drug mix," says ICORE President Alan Lotvin, MD.
While payers have long been concerned about rising specialty drug costs, tracking specialty drug spending has been notoriously difficult because of a lack of detail and uniformity in the data collected.
INJECTABLES ADD TO CANCER CARE
The report found specialty drugs related to cancer care represented more than half of medical injectable costs. Injectable chemotherapy accounted for more than one-third of all medical injectable costs, but chemotherapy support medicines (granulocyte colony-stimulating factors and erythropoiesis-stimulating agents) added significantly to the total cost of cancer care.
What's more, spending on injectable chemotherapy dwarfed the amount spent on oral chemotherapy. In 2009 a typical commercial payer covering 1 million lives spent nearly $32 million on injectable chemotherapies: eight times more than it would have spent on oral chemotherapies, according to the report.
Biologic response modifiers used to treat autoimmune disorders, such as rheumatology, represented the second largest therapeutic spending category.
"That's been a rapidly growing class that often surprises people," says Dr. Lotvin, noting that the drugs are now used for a broad array of indications including gastrointestinal conditions like Crohn's disease and skin conditions like psoriasis.
While intravenous immunoglobulin (IVIG) constituted only about $2.2 million of the typical payer's specialty medical drug spending, for example, the report projects that total IVIG spending-including home infusion and treatments administered through the specialty pharmacy channel-was probably three times as much.
Overall, key cost drivers include: the expansion of indications for certain chemotherapies; the U.S. Food and Drug Administration approval of several new therapies; and price inflation, which the firm estimates to be 4%.
Given the magnitude and upward trajectory of these costs, it's no surprise that payers are looking for ways to manage their spending. Dr. Lotvin says that many plans have put fee schedules in place, started to focus on utilization management, and have begun developing and managing formularies.
More than half the plans surveyed receive rebates for at least one injectable drug paid under the medical benefit, most often for rheumatoid arthritis drugs. Larger health plans are about 50% more likely to have a rebate program in place.
"Pricing in the industry has gotten so aggressive that you really can't talk about discounts anymore," he says. "You need to talk about clinically based management approaches, and you have to make sure what you are doing is absolutely within the scope of maintaining and improving clinical practice."
Because a growing number of conditions, such as multiple sclerosis and Crohn's, are treated with a broad mix of drugs, payers need to find an integrated approach to managing pharmacy and medical benefits data.
"That won't be easy," he says. "It's going to take diligence, focus, sweat and a recognition by the market that this is important."
-Shelly Reese
What Payers Need to Know As Retail Pharmacies Move Into Primary Care
September 6th 2023Healthcare beyond the doors of the doctor’s office has the potential to offer more care to more people. But payers need to think about how to ensure that care is consistent. Regardless of the setting, care decisions must be based on evidence-based content and supported with strong patient education.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Addressing the Barriers of Medication Adherence Through Digital Health
July 9th 2023Tony Little, ND, VP of Solutions Architecture at Prescryptive Health, shares how the organization is tackling one of the biggest barriers to prescription adherence — cost — through a digital app, among the other barriers patients face.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen